AbbVie (ABBV) and Gubra announced a license agreement to develop GUB014295, a long-acting amylin analog for the treatment of obesity. Under the terms of the agreement, AbbVie will lead development and commercialization activities of GUB014295 globally. Gubra will receive $350M in total upfront payment and will be eligible to receive up to $1.88B in development, commercial and sales milestone payments with tiered royalties on global net sales. The transaction closure is subject to regulatory approvals and other customary closing conditions.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie: Strong Performance but High Valuation and Limited Catalysts Justify Hold Rating
- AbbVie announces CHMP opinion recommending approval of upadacitinib
- Mustang Bio exits lease for Massachusetts facility, divests equipment
- Deutsche downgrades Merck ahead of Keytruda 2028 expiration
- Biotech Alert: Searches spiking for these stocks today